Related Experiment Video

Updated: Jun 4, 2026

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis
07:57

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis

Published on: December 8, 2011

Prospects for development of a vaccine to prevent and control vaginal candidiasis

Paul L Fidel1, Jim E Cutler

  • 1Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA, pfidel@lsuhsc.edu.

Current Infectious Disease Reports
|February 11, 2011
PubMed

Insights

Developing a vaccine for recurrent vulvovaginal candidiasis (RVVC) shows promise with a new β-glucan conjugate. While results in a mouse model were modest, live imaging improved fungal burden assessment, suggesting a path forward for RVVC vaccine research.

Area of Science:

  • Immunology
  • Vaccinology
  • Mycology

Background:

  • Recurrent vulvovaginal candidiasis (RVVC) affects numerous women, necessitating effective preventative strategies.
  • Current vaccine approaches for RVVC have yielded limited success.

Purpose of the Study:

  • To review the latest vaccine study for RVVC using a novel β-glucan conjugate.
  • To evaluate the efficacy of this candidate in a preclinical mouse model and assess new imaging techniques for quantifying fungal burden.

Main Methods:

  • A β-glucan conjugate vaccine with a compatible adjuvant was tested in a mouse model of vaginitis.
  • Candida albicans expressing luciferase was used for challenge, with fungal burden quantified via live animal imaging (biophotonics).

Main Results:

  • The vaccine demonstrated modest protection against RVVC in the mouse model.
  • Protection was associated with the development of β-glucan antibodies.
  • Live animal imaging provided a less variable method for assessing fungal burden compared to traditional plate counts.

Conclusions:

  • While the tested vaccine candidate showed limited efficacy, advances in imaging technology offer improved methods for evaluating RVVC vaccine effectiveness.
  • Further research is needed to identify a clinically viable vaccine candidate for recurrent vulvovaginal candidiasis.

More Related Videos

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Modeling Healthy and Dysbiotic Vaginal Microenvironments in a Human Vagina-on-a-Chip08:15

Modeling Healthy and Dysbiotic Vaginal Microenvironments in a Human Vagina-on-a-Chip

Published on: February 16, 2024

Related Concept Videos

Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
Genital Herpes01:23

Genital Herpes

Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...